Cancer

Photo

News • Oncology

Nanoparticle creates ‘wave of destruction’ in cancer cells

Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer. Now, the ultrasmall particles – developed more than a dozen years ago by Ulrich Wiesner, the Spencer T. Olin Professor of Engineering at Cornell University – have shown they can do something even better: kill cancer cells without attaching a cytotoxic drug.

Photo

News • Melanoma treatment

Dermatology develops an effective immunotherapy against solid cancer

Melanomas account among the eight most frequent deadly cancers in Europe and Northern America. Two major clinical criteria separate melanomas from most other cancers: the risk to die from a melanoma is a question of being less or more than 1 mm – and not a question of cm. About 95% of patients with melanomas ≤0.5 mm in thickness are clinically cured by early detection and appropriate melanoma…

News • Proton Adaptive Therapy

IBA to open the path towards adaptive proton therapy

IBA (Ion Beam Applications) today unveils its unique platform, 'Leading the PATh', which gathers the leading experts in the field of proton therapy all in one place. It is anticipated that 'Leading the PATh' will enable the worldwide medical community to shape the most efficient Proton Adaptive Therapy (PATh), a proton therapy process which improves the accuracy of what is considered to be the…

Photo

Solid-State nanopores unravel twisted DNA mystery

Cancer thrives when mutated cells undergo frequent division. Most anti-cancer drugs work by inserting themselves in between the DNA base pairs that encode our genetic information. This process is known as intercalation, and it can result in subtle changes to the DNA molecule’s geometric shape or tertiary structure. These structural changes interfere with the DNA’s transcription and a cell’s…

Photo

News • Oncology

Nanovaccine could enhance cancer immunotherapy

NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects. The nanovaccine helps to efficiently deliver a unique DNA sequence to immune cells – a sequence derived from bacterial DNA and used to trigger an immune reaction. The nanovaccine also protects the DNA from being destroyed inside the body, where…

News • Oncology

Infra-red light to deteact early signs of oesophageal cancer

Researchers at the Cancer Research UK Cambridge Institute sprayed a dye on oesophageal tissue samples taken from people with Barrett’s oesophagus – a condition that increases the risk of developing oesophageal cancer. The dye sticks to healthy oesophageal cells but not to pre-cancerous cells. They then shone near-infrared light - which is just beyond the red colours that our eyes can normally…

Photo

News • Oncology

Loophole for cancer cells

Many cancers only become a mortal danger if they form metastases elsewhere in the body. Such secondary tumours are formed when individual cells break away from the main tumour and travel through the bloodstream to distant areas of the body. To do so, they have to pass through the walls of small blood vessels. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim and…

Photo

Interview • Fighting cancer

The first Spanish oncology forum

When two Spanish oncologists launched the first independent Spanish oncology forum this May in Madrid, European Hospital’s correspondent spoke with Dr Javier Cortés, co-organiser of the event, to find out more about its expected impact in their field.

Photo

News • Research

New Biomarker for cancer immunotherapy?

The Ligand PD-L1 is one of the most important targets for cancer immunotherapy with checkpoint inhibitors. But not all tumors have sufficient quantities of PD-L1 ligands on their surface. Scientists from the German Cancer Consortium (DKTK) have now shown that different types of cancer possess different quantities of PD-L1-Gen copies. Genetic analysis of the PD-L1 gene may in the future help to…

Photo

Article • Drug delivery

Biotherapeutics strike cancer cell growth

Many drug treatments do not work due to their poor ability to reach their intended targets inside patients’ cells. To address this, researchers at Cardiff University’s Schools of Pharmacy and Pharmaceutical Sciences, and Biosciences have designed a highly efficient method to improve the delivery of therapeutic molecules into diseased cells such as those in stomach cancer, breast cancer and…

Photo

Microfluidic device tests effects of electric fields on cancer cells

Researchers at Massachusetts Institute of Technology research center in Singapore have developed a new microfluidic device that tests the effects of electric fields on cancer cells. They observed that a range of low-intensity, middle-frequency electric fields effectively stopped breast and lung cancer cells from growing and spreading, while having no adverse effect on neighboring healthy cells.

Photo

News • Dividing T cells

Target for improving cancer immunotherapy

When an immune T cell divides into two daughter cells, the activity of an enzyme called mTORC1, which controls protein production, splits unevenly between the progeny, producing two cells with different properties. Such "asymmetric division," uncovered by Johns Hopkins Kimmel Cancer Center researchers using lab-grown cells and specially bred mice, could offer new ways to enhance cancer…

Photo

Article • Mammography

The dedicated prone breast biopsy table

Breast tomosynthesis imaging, Holo­gic calls it 3-D mammography, is proving to be the best modality to image breast cancer. ‘The Hologic tomosynthesis system has demonstrated superior clinical performance to conventional 2-D mammography in a number of metrics, in particular showing improved detection of invasive cancers and reductions in recall rate,’ the manufacturer reports, adding: ‘Now…

Photo

News • Virology

Tricks of ticking time bomb Hepatitis B virus

Hepatitis B virus (HBV) causes hepatitis B, an infectious disease that afflicts 230 million people worldwide, thereof 440 000 in Germany. Persistence of the virus in liver cells leads to progressive organ damage in the patient and contributes to a high risk of cirrhosis and liver cancer development. Providing a new paradigm to hepatitis B understanding, researchers at the German Cancer Research…

141 show more articles
Subscribe to Newsletter